ArticleMolecular therapy. Oncology2026
EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.
Gábor Bakos et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.